Your browser doesn't support javascript.
loading
Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization.
Kusumoto, Yoshifumi; Hayashi, Kyohei; Sato, Soichiro; Yamada, Toru; Kozono, Iori; Nakata, Zenzaburo; Asada, Naoya; Mitsuki, Shungo; Watanabe, Ayahisa; Wakasa-Morimoto, Chiaki; Uemura, Kentaro; Arita, Shuhei; Miki, Shinobu; Mizutare, Tohru; Mikamiyama, Hidenori.
Afiliação
  • Kusumoto Y; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Hayashi K; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Sato S; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Yamada T; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Kozono I; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Nakata Z; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Asada N; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Mitsuki S; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Watanabe A; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Wakasa-Morimoto C; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Uemura K; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Arita S; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Miki S; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Mizutare T; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
  • Mikamiyama H; Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd. 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
ACS Med Chem Lett ; 13(10): 1634-1641, 2022 Oct 13.
Article em En | MEDLINE | ID: mdl-36262395
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article